genOway’s upcoming congresses – Come and meet us!

Nov 1-5, 2023: SITC, San Diego, CA

☑ Cell depleting agents assessment in preclinical models

☑ Myeloid cells contribution is key to reproduce CRS pathophysiology induced by T-cell engagers in BRGSF-HIS models

July 18-20, 2023: 3rd Annual Tumor Myeloid-Directed Therapies Summit, Boston, MA

How to enhance translatability of myeloid-targeted therapies in preclinical models

☑ Outlining BRGSF-HIS mice: Immunodeficient mice displaying functional human lymphoid and myeloid compartments, without GvHD and side effects

☑ Examining myeloid cells functionality and assessing immune modulation induced by biologics in BRGSF-HIS model

☑ Showcase of assessment of immune targeting agents in immune checkpoint humanized model

May 26, 2023: 43rd Workshop of the Korean Society of Non-Clinical Study (KSNS), Suwon, KR

Precise and translational preclinical models for assessment of immune-targeting agents:

☑ Outlining BRGSF-HIS mice: immunodeficient mice displaying functional human lymphoid and myeloid compartments, without side effects

☑ Assessing efficacy and toxicity induced by immune checkpoint inhibitors, cell engagers and combo therapies in BRGSF-HIS mice, which displays a wide therapeutic window

☑ Showcase of assessment of immune targeting agents in syngeneic humanized models

May 9-11, 2023: STING & TLR-Targeting Therapies Summit, Boston, MA

Profiling STING and TLR-Targeted Therapies in Humanized Preclinical Models:

☑ Focus on BRGS-HIS CD34+ reconstituted mice featuring human lymphoid and myeloid compartments and syngeneic humanized mouse models

☑ Characterization of the immune response in the mice

☑ Showcasing an assessment of STING and TR targeting agents in these models

April 25-27, 2023: 5th Annual Cell Engager Summit, Boston, MA

Challenging the predictability of preclinical models for assessment of cell engagers:

☑ Focus on BRGSF-HIS hCD34+-reconstituted mice featuring human lymphoid and myeloid compartments and syngeneic humanized mouse models

☑ Characterization of the immune response in these mice

☑ Assessment of efficacy and irAE induced by cell engagers

April 19–20, 2023: Fc Receptor Pathway Targeted Therapies, Boston, MA

How to enhance the transferability of Fc-targeted therapies in preclinical models? A question that Kader Thiam, Sr VP, Discovery - Preclinical Models & Services Kader Thiam answered brilliantly in his talk in Boston. He mentioned in particular:

☑ How recapitulating human Fc receptors expression pattern in mice

☑ How investigating biologics’ Fc modifications on effector function and pharmacokinetics in humanized models

☑ Innovative genOway mouse models expressing human Fc receptors, tools for translational evaluation of Fc receptor-targeted therapies

April 14–19, 2023: AACR, Orlando, FL

The genOway Team was present at this event with a booth to discuss about our highly physiologically relevant humanized preclinical models and see how they can help accelerate scientific research project, from drug discovery, through preclinical studies, to IND filing. It also took part in the poster session with a poster about our BRGSF-HIS mouse model explaining how functional human myeloid cells in humanized BRGSF-HIS mice allow assessment of myeloid-directed therapies.

March 28–29, 2023: Immuno Series UK, London

Kader Thiam, Sr VP, Discovery - Preclinical Models & Services, presented the talk: "Applicability and complementarity of syngeneic and BRGSF-HIS (Human Immune System) mouse models to assess efficacy and mechanism of action of mono- and combo-immunotherapies".

January 24–26, 2023: Tumor Models San Francisco 2023

genOway was present at this event with a booth. Kader Thiam presented a lecture titled “Precise and Translational Models for Assessment of Immune-Targeting Agents”:

☑ Outlining BRGSF-HIS mice: immunodeficient mice displaying functional human lymphoid and myeloid compartments, without side effects

☑ Assessing efficacy and toxicity induced by immune checkpoint inhibitors, cell engagers and combotherapies in BRGSF-HIS mice, which displays a wide therapeutic window

☑ Showcase of assessment of immune targeting agents in immune checkpoint humanized models

January 18, 2023: genOway's webinar on Immunotherapy & Preclinical Models

"Assessing efficacy and MoA of mono and combo immunotherapies in preclinical humanized models" (Organized by genOway with the support of BioInsights)

The development of innovative models allows for a more efficient evaluation of new cancer treatments and identification of predictive biomarkers of response right from the early phases of development of a therapeutic molecule until the late preclinical phases.

Discover through our one-hour webinar how our preclinical mouse models enable pharmaceutical industries and biotechs to validate the efficacy and nontoxicity of their antibodies in immunotherapies.

Kader Thiam (Senior Vice President, Discovery – Preclinical Models & Services, genOway) provided a broad view of our preclinical model pipeline.

Arjun Surya (Chief Executive Officer & Chief Scientific Officer, Curadev Pharma) discussed the assessment of their STING targeting agents in our humanized STING Knock-in mouse model.

Edward van der Horst (Senior Vice President, Sensei Biotherapeutics) discussed the conditionally active antibody SNS-101 and its inhibition of VISTA immune checkpoint activity in the acidic tumor microenvironment, leading to significant enhancement of antitumor effects in combination with anti-PD-1 antibodies in multiple syngeneic tumor models.

Through this webinar, you can learn more about:

• The advantages of BRGSF-HIS models (with functional human lymphoid and myeloid compartments) to assess human targeted therapies, and investigate in particular the potential toxicity of compounds
• The advantages of immunocompetent models which feature humanized immune checkpoints (in which the crosstalk between syngeneic tumor, immune and stroma cells is functional) for the investigation of the efficacy and mechanisms of action
• The applicability and complementarity of syngeneic and BRGSF-HIS models to assess efficacy and MoA of immunotherapies